603567.SH
珍宝岛
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.32
−5.67%Year over year
Reported trailing growth
- Revenue
- -75.2%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +386.3%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -42.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +1120.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026